Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice

The characteristics of the skin tumor promotion response with anthrone derivatives has been further examined in SENCAR mice. Chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) was an effective skin tumor promoter when applied twice weekly with dose-dependent increases in both papillomas and squamous ce...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 1987-07, Vol.47 (14), p.3783-3790
Hauptverfasser: KRUSZEWSKI, F. H, CONTI, C. J, DIGIOVANNI, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3790
container_issue 14
container_start_page 3783
container_title Cancer research (Chicago, Ill.)
container_volume 47
creator KRUSZEWSKI, F. H
CONTI, C. J
DIGIOVANNI, J
description The characteristics of the skin tumor promotion response with anthrone derivatives has been further examined in SENCAR mice. Chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) was an effective skin tumor promoter when applied twice weekly with dose-dependent increases in both papillomas and squamous cell carcinomas between 25 and 100 nmol/mouse. A similar dose-response relationship for papilloma and carcinoma formation was observed when chrysarobin was applied once weekly. Interestingly, chrysarobin was approximately twice as active as a skin tumor promoter when applied once weekly versus twice weekly. Doses of 25,100, and 220 nmol/mouse gave maximal papilloma responses of 2.90, 8.15, and 9.38 versus 0.73, 4.70, and 5.42 papillomas/mouse, respectively, in mice initiated with 25 nmol 7,12-dimethylbenz(a)anthracene. Thus, unlike 12-O-tetradecanoylphorbol-13-acetate (TPA), where a twice weekly application frequency is optimal, application of anthrone promoters such as chrysarobin once weekly is a more optimal frequency for papilloma development. Chrysarobin was also a much more effective skin tumor promoter when the start of promotion was delayed by an additional 10 weeks. Thus, groups of mice initiated with 10 nmol 7,12-dimethylbenz(a)anthracene and having promotion started in either the 3rd or the 13th week after initiation had maximal responses of 5.6 or 11.0 papillomas/mouse, respectively. In addition, the rate of papilloma development was faster in the delayed promotion group. The progression of papillomas to carcinomas was examined in all chrysarobin-treated groups and compared with three groups of mice treated with 3.4 nmol TPA. After 60 weeks of promotion, the anthrone promoter-treated groups had carcinoma:papilloma ratios 2.5 to 5.0 times higher than the TPA-treated groups. This was due primarily to the fact that similar carcinoma responses were observed in both anthrone- and TPA-treated mice at optimal promoting doses whereas the papilloma responses were significantly lower in the former groups. The data suggest that anthrone derivatives are very efficient tumor promoters. The results are further discussed in terms of mechanisms of skin tumor promotion.
format Article
fullrecord <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_3109733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3109733</sourcerecordid><originalsourceid>FETCH-LOGICAL-h269t-77151e028462b1c1dbe54a3c85e79c7b8667e1ffa12be6a161a2a299b92846e93</originalsourceid><addsrcrecordid>eNo9j9tKxDAQhoMoa119BKEX3hZyaJrkcinrARYFT7fLJE1tdNuUpHtRn95WizAwfPN_MzAnKCGcyUzkOT9FCcZYZjwX9BxdxPg5ISeYr9CKEawEYwl6LxsIYAYb3DcMznepr9P45bp0OLY-pH3wrf-dQ1fN9BFsjDPrMTVNGCMEryd9qpftY7l5Tltn7CU6q-EQ7dXS1-jtdvta3me7p7uHcrPLGlqoIROCcGIxlXlBNTGk0pbnwIzkVigjtCwKYUldA6HaFkAKAhSoUlrNK1axNbr-u9sfdWurfR9cC2HcL_9N-c2SQzRwqAN0xsV_TTI8WYL9AP2BWfc</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>KRUSZEWSKI, F. H ; CONTI, C. J ; DIGIOVANNI, J</creator><creatorcontrib>KRUSZEWSKI, F. H ; CONTI, C. J ; DIGIOVANNI, J</creatorcontrib><description>The characteristics of the skin tumor promotion response with anthrone derivatives has been further examined in SENCAR mice. Chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) was an effective skin tumor promoter when applied twice weekly with dose-dependent increases in both papillomas and squamous cell carcinomas between 25 and 100 nmol/mouse. A similar dose-response relationship for papilloma and carcinoma formation was observed when chrysarobin was applied once weekly. Interestingly, chrysarobin was approximately twice as active as a skin tumor promoter when applied once weekly versus twice weekly. Doses of 25,100, and 220 nmol/mouse gave maximal papilloma responses of 2.90, 8.15, and 9.38 versus 0.73, 4.70, and 5.42 papillomas/mouse, respectively, in mice initiated with 25 nmol 7,12-dimethylbenz(a)anthracene. Thus, unlike 12-O-tetradecanoylphorbol-13-acetate (TPA), where a twice weekly application frequency is optimal, application of anthrone promoters such as chrysarobin once weekly is a more optimal frequency for papilloma development. Chrysarobin was also a much more effective skin tumor promoter when the start of promotion was delayed by an additional 10 weeks. Thus, groups of mice initiated with 10 nmol 7,12-dimethylbenz(a)anthracene and having promotion started in either the 3rd or the 13th week after initiation had maximal responses of 5.6 or 11.0 papillomas/mouse, respectively. In addition, the rate of papilloma development was faster in the delayed promotion group. The progression of papillomas to carcinomas was examined in all chrysarobin-treated groups and compared with three groups of mice treated with 3.4 nmol TPA. After 60 weeks of promotion, the anthrone promoter-treated groups had carcinoma:papilloma ratios 2.5 to 5.0 times higher than the TPA-treated groups. This was due primarily to the fact that similar carcinoma responses were observed in both anthrone- and TPA-treated mice at optimal promoting doses whereas the papilloma responses were significantly lower in the former groups. The data suggest that anthrone derivatives are very efficient tumor promoters. The results are further discussed in terms of mechanisms of skin tumor promotion.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 3109733</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>9,10-Dimethyl-1,2-benzanthracene ; Animals ; Anthracenes ; Biological and medical sciences ; Carcinogenesis, carcinogens and anticarcinogens ; Chemical agents ; Dose-Response Relationship, Drug ; Female ; Medical sciences ; Mice ; Mice, Inbred Strains ; Papilloma - chemically induced ; Papilloma - pathology ; Skin Neoplasms - chemically induced ; Skin Neoplasms - pathology ; Tetradecanoylphorbol Acetate ; Tumors</subject><ispartof>Cancer research (Chicago, Ill.), 1987-07, Vol.47 (14), p.3783-3790</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=8307337$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3109733$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KRUSZEWSKI, F. H</creatorcontrib><creatorcontrib>CONTI, C. J</creatorcontrib><creatorcontrib>DIGIOVANNI, J</creatorcontrib><title>Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>The characteristics of the skin tumor promotion response with anthrone derivatives has been further examined in SENCAR mice. Chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) was an effective skin tumor promoter when applied twice weekly with dose-dependent increases in both papillomas and squamous cell carcinomas between 25 and 100 nmol/mouse. A similar dose-response relationship for papilloma and carcinoma formation was observed when chrysarobin was applied once weekly. Interestingly, chrysarobin was approximately twice as active as a skin tumor promoter when applied once weekly versus twice weekly. Doses of 25,100, and 220 nmol/mouse gave maximal papilloma responses of 2.90, 8.15, and 9.38 versus 0.73, 4.70, and 5.42 papillomas/mouse, respectively, in mice initiated with 25 nmol 7,12-dimethylbenz(a)anthracene. Thus, unlike 12-O-tetradecanoylphorbol-13-acetate (TPA), where a twice weekly application frequency is optimal, application of anthrone promoters such as chrysarobin once weekly is a more optimal frequency for papilloma development. Chrysarobin was also a much more effective skin tumor promoter when the start of promotion was delayed by an additional 10 weeks. Thus, groups of mice initiated with 10 nmol 7,12-dimethylbenz(a)anthracene and having promotion started in either the 3rd or the 13th week after initiation had maximal responses of 5.6 or 11.0 papillomas/mouse, respectively. In addition, the rate of papilloma development was faster in the delayed promotion group. The progression of papillomas to carcinomas was examined in all chrysarobin-treated groups and compared with three groups of mice treated with 3.4 nmol TPA. After 60 weeks of promotion, the anthrone promoter-treated groups had carcinoma:papilloma ratios 2.5 to 5.0 times higher than the TPA-treated groups. This was due primarily to the fact that similar carcinoma responses were observed in both anthrone- and TPA-treated mice at optimal promoting doses whereas the papilloma responses were significantly lower in the former groups. The data suggest that anthrone derivatives are very efficient tumor promoters. The results are further discussed in terms of mechanisms of skin tumor promotion.</description><subject>9,10-Dimethyl-1,2-benzanthracene</subject><subject>Animals</subject><subject>Anthracenes</subject><subject>Biological and medical sciences</subject><subject>Carcinogenesis, carcinogens and anticarcinogens</subject><subject>Chemical agents</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Papilloma - chemically induced</subject><subject>Papilloma - pathology</subject><subject>Skin Neoplasms - chemically induced</subject><subject>Skin Neoplasms - pathology</subject><subject>Tetradecanoylphorbol Acetate</subject><subject>Tumors</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j9tKxDAQhoMoa119BKEX3hZyaJrkcinrARYFT7fLJE1tdNuUpHtRn95WizAwfPN_MzAnKCGcyUzkOT9FCcZYZjwX9BxdxPg5ISeYr9CKEawEYwl6LxsIYAYb3DcMznepr9P45bp0OLY-pH3wrf-dQ1fN9BFsjDPrMTVNGCMEryd9qpftY7l5Tltn7CU6q-EQ7dXS1-jtdvta3me7p7uHcrPLGlqoIROCcGIxlXlBNTGk0pbnwIzkVigjtCwKYUldA6HaFkAKAhSoUlrNK1axNbr-u9sfdWurfR9cC2HcL_9N-c2SQzRwqAN0xsV_TTI8WYL9AP2BWfc</recordid><startdate>19870715</startdate><enddate>19870715</enddate><creator>KRUSZEWSKI, F. H</creator><creator>CONTI, C. J</creator><creator>DIGIOVANNI, J</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19870715</creationdate><title>Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice</title><author>KRUSZEWSKI, F. H ; CONTI, C. J ; DIGIOVANNI, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h269t-77151e028462b1c1dbe54a3c85e79c7b8667e1ffa12be6a161a2a299b92846e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>9,10-Dimethyl-1,2-benzanthracene</topic><topic>Animals</topic><topic>Anthracenes</topic><topic>Biological and medical sciences</topic><topic>Carcinogenesis, carcinogens and anticarcinogens</topic><topic>Chemical agents</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Papilloma - chemically induced</topic><topic>Papilloma - pathology</topic><topic>Skin Neoplasms - chemically induced</topic><topic>Skin Neoplasms - pathology</topic><topic>Tetradecanoylphorbol Acetate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KRUSZEWSKI, F. H</creatorcontrib><creatorcontrib>CONTI, C. J</creatorcontrib><creatorcontrib>DIGIOVANNI, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KRUSZEWSKI, F. H</au><au>CONTI, C. J</au><au>DIGIOVANNI, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1987-07-15</date><risdate>1987</risdate><volume>47</volume><issue>14</issue><spage>3783</spage><epage>3790</epage><pages>3783-3790</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>The characteristics of the skin tumor promotion response with anthrone derivatives has been further examined in SENCAR mice. Chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) was an effective skin tumor promoter when applied twice weekly with dose-dependent increases in both papillomas and squamous cell carcinomas between 25 and 100 nmol/mouse. A similar dose-response relationship for papilloma and carcinoma formation was observed when chrysarobin was applied once weekly. Interestingly, chrysarobin was approximately twice as active as a skin tumor promoter when applied once weekly versus twice weekly. Doses of 25,100, and 220 nmol/mouse gave maximal papilloma responses of 2.90, 8.15, and 9.38 versus 0.73, 4.70, and 5.42 papillomas/mouse, respectively, in mice initiated with 25 nmol 7,12-dimethylbenz(a)anthracene. Thus, unlike 12-O-tetradecanoylphorbol-13-acetate (TPA), where a twice weekly application frequency is optimal, application of anthrone promoters such as chrysarobin once weekly is a more optimal frequency for papilloma development. Chrysarobin was also a much more effective skin tumor promoter when the start of promotion was delayed by an additional 10 weeks. Thus, groups of mice initiated with 10 nmol 7,12-dimethylbenz(a)anthracene and having promotion started in either the 3rd or the 13th week after initiation had maximal responses of 5.6 or 11.0 papillomas/mouse, respectively. In addition, the rate of papilloma development was faster in the delayed promotion group. The progression of papillomas to carcinomas was examined in all chrysarobin-treated groups and compared with three groups of mice treated with 3.4 nmol TPA. After 60 weeks of promotion, the anthrone promoter-treated groups had carcinoma:papilloma ratios 2.5 to 5.0 times higher than the TPA-treated groups. This was due primarily to the fact that similar carcinoma responses were observed in both anthrone- and TPA-treated mice at optimal promoting doses whereas the papilloma responses were significantly lower in the former groups. The data suggest that anthrone derivatives are very efficient tumor promoters. The results are further discussed in terms of mechanisms of skin tumor promotion.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>3109733</pmid><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 1987-07, Vol.47 (14), p.3783-3790
issn 0008-5472
1538-7445
language eng
recordid cdi_pubmed_primary_3109733
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects 9,10-Dimethyl-1,2-benzanthracene
Animals
Anthracenes
Biological and medical sciences
Carcinogenesis, carcinogens and anticarcinogens
Chemical agents
Dose-Response Relationship, Drug
Female
Medical sciences
Mice
Mice, Inbred Strains
Papilloma - chemically induced
Papilloma - pathology
Skin Neoplasms - chemically induced
Skin Neoplasms - pathology
Tetradecanoylphorbol Acetate
Tumors
title Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T08%3A58%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20skin%20tumor%20promotion%20and%20progression%20by%20chrysarobin%20in%20SENCAR%20mice&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=KRUSZEWSKI,%20F.%20H&rft.date=1987-07-15&rft.volume=47&rft.issue=14&rft.spage=3783&rft.epage=3790&rft.pages=3783-3790&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E3109733%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/3109733&rfr_iscdi=true